中国肿瘤生物治疗杂志2025，Vol.32Issue(10)：1071-1077,7.DOI:10.3872/j.issn.1007-385x.2025.10.010
西达苯胺联合CHOP方案治疗初诊外周T细胞淋巴瘤的疗效及预后分析
Efficacy and prognostic analysis of chidamide combined with CHOP in the treatment of preliminarily diagnosed peripheral T-cell lymphoma
摘要
Abstract
Objective:To investigate the clinical efficacy of histone deacetylase(HDAC)inhibitor chidamide combined with CHOP in the treatment of preliminarily diagnosed peripheral T-cell lymphoma(PTCL)and to analyze the factors influencing its prognosis.Methods:Clinical data were collected from patients who were preliminarily diagnosed with PTCL,but had not received radiotherapy or chemotherapy at the Affiliated Hospital of Nantong University between April 2012 and August 2022.The patients were divided into two groups,based on the frontline treatment regimen:the chidamide+CHOP group(n=20)and the CHOP group(n=24).The differences in clinicopathological characteristics between the two groups were compared by chi-square test or Fisher's exact test.Survival curves were generated by Kaplan-Meier method,and univariate survival analysis was conducted by Log-Rank test.Subgroup analysis was performed to assess the survival outcomes of patients in the chidamide+CHOP group,and interaction tests were conducted to assess the factors that might influence the difference in survival prognosis between the two groups.Results:The baseline levels of the two groups were comparable in age,gender,and tumor stage,but there were more AITL patients(70.8%vs 15%)and fewer PTCL-NOS patients(16.7%vs 30%)in the chidamide+CHOP group.Efficacy analysis revealed that the median PFS was significantly longer in patients treated with chidamide+CHOP(7 months vs 3 months,P=0.032),and their median OS was also significantly longer(20 months vs 6 months,P=0.004).Univariate prognostic analysis revealed that PTCL patients with B symptoms had significantly poorer PFS(P=0.053)and OS(P=0.065)than PTCL patients without B symptoms;and patients with elevated baseline LDH levels had a worse OS(P=0.056).Further subgroup analysis of efficacy revealed that,among patients with normal baseline serum ferritin levels,those in the chidamide+CHOP group had significantly better PFS compared with those in the CHOP group(95%CI[1.14,43.58]).The interaction test between serum ferritin levels and treatment regimens demonstrated statistical significance(P=0.042).Conclusion:The combination of chidamide and CHOP has survival benefits for patients preliminarily diagnosed with PTCL,and baseline serum ferritin levels may serve as a potential predictor for combination therapy.关键词
外周T细胞淋巴瘤/西达苯胺/组蛋白乙酰化/化疗/血清铁蛋白/预后Key words
peripheral T lymphoma(PTCL)/chidamide/histone deacetylase(HDAC)/chemotherapy/serum ferritin/prognosis分类
临床医学引用本文复制引用
蒋永宁,龚贝琦,王红,陈洁,张亚平,施文瑜..西达苯胺联合CHOP方案治疗初诊外周T细胞淋巴瘤的疗效及预后分析[J].中国肿瘤生物治疗杂志,2025,32(10):1071-1077,7.基金项目
2024年度省江苏基础研究计划(自然科学基金)面上项目(No.BK20241837) （自然科学基金）
江苏省研究型医院发展基金课题(No.YJXYY202204-XKB17) （No.YJXYY202204-XKB17）
白求恩·肿瘤临床研究计划项目(No.BCF-XD-ZL-20220118-001) （No.BCF-XD-ZL-20220118-001）
2022年度南通市基础科学研究和社会民生科技计划项目(No.MS22022111) （No.MS22022111）
南通市"十四五"科教强卫工程重点项目——肿瘤学临床医学中心(No.NTYXZX18) （No.NTYXZX18）
江苏省"十四五"卫生健康科教能力提升工程——医学重点学科(肿瘤学)(No.ZDXK202234) （肿瘤学）
